---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041417"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:15:44.693678+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports Q2 2023 net loss of $34.8M; cash at $446.1M

## Summary
- Net loss before noncontrolling interest $34.8M for Q2 2023 vs $22.1M in Q2 2022.
- R&D expenses $26.4M (up from $11.6M) driven by Phase 3 trial and manufacturing expansion.
- Cash, equivalents and marketable securities $446.1M as of June 30, 2023, down from $490.3M at Dec 31, 2022.
- Purchased 210,000 sq ft Greensboro facility; $458M investment planned by 2027 with $33.7M in tax incentives.
- Phase 3 proact 1 enrolling; interim data expected end 2024; proact 2 enrollment expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-041417
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/0000950170-23-041417-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/prok-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041417
- JSON: https://secwatch.observer/filing/0000950170-23-041417.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041417.txt

## Key facts
- Earnings Releases
  PROKIDNEY CORP. reported second quarter ended June 30, 2023 results: net income Net loss before noncontrolling interest was $34.8 million.
  - Period: second quarter ended June 30, 2023
  - Net income: Net loss before noncontrolling interest was $34.8 million
  - Result: reported results
  source text: ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000095017023041417/0000950170-23-041417-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.